checkmate
pharmaceuticals
present
upcoming
jefferies
virtual
london
healthcare
conference
cambridge
globe
newswire
checkmate
pharmaceuticals
nasdaq
cmpi
checkmate
clinical
stage
biotechnology
company
focused
developing
proprietary
technology
harness
power
immune
system
combat
cancer
today
announced
barry
labinger
ceo
present
upcoming
jefferies
virtual
london
healthcare
conference
presentation
scheduled
et
tuesday
november
webcast
live
webcast
presentation
accessed
events
presentations
investors
section
checkmate
website
archived
copy
webcast
available
checkmate
website
approximately
days
event
checkmate
pharmaceuticals
checkmate
pharmaceuticals
clinical
stage
biotechnology
company
focused
developing
proprietary
technology
harness
power
immune
system
combat
cancer
checkmate
product
candidate
differentiated
agonist
delivered
biologic
particle
designed
trigger
body
innate
immune
system
attack
tumors
combination
therapies
checkmate
goal
leverage
proprietary
technology
discover
develop
commercialize
transformative
treatments
fight
cancer
information
regarding
checkmate
available
forward
looking
statements
various
statements
release
statements
within
meaning
private
securities
litigation
reform
act
amended
including
words
limited
anticipate
believe
could
expect
estimate
design
goal
intend
may
might
objective
plan
predict
project
target
likely
would
negative
terms
similar
expressions
words
identify
statements
statements
based
upon
current
expectations
involve
risks
changes
circumstances
assumptions
uncertainties
statements
include
regarding
product
candidate
including
development
therapeutic
potential
advancement
clinical
preclinical
pipeline
expectations
regarding
results
analysis
data
statements
read
guarantee
future
performance
results
may
accurate
indications
performance
results
achieved
positive
results
clinical
study
may
necessarily
predictive
results
future
ongoing
clinical
studies
statements
subject
risks
uncertainties
including
related
development
product
candidate
including
delays
ongoing
planned
preclinical
clinical
trials
impact
ongoing
pandemic
business
operations
clinical
supply
plans
risks
inherent
drug
development
process
risks
regarding
accuracy
estimates
expenses
timing
development
capital
requirements
need
additional
financing
obtaining
maintaining
protecting
intellectual
property
additional
risks
discussed
sections
titled
risk
factors
management
discussion
analysis
financial
condition
results
operations
prospectus
dated
august
filed
securities
exchange
commission
sec
pursuant
rule
b
securities
act
amended
available
sec
website
company
subsequent
filings
sec
